Utilizing cytoDRiVE technology, OBX-115 aims to regulate membrane-bound IL15 in conjunction with the drug acetazolamide, showing potential benefits for patients with advanced melanoma who are resistant to immune checkpoint inhibitors.

One of Obsidian's key clinical programs, OBX-115, is an engineered tumor-infiltrating lymphocyte (TIL) therapy designed to enhance persistence, antitumor activity, and safety for patients suffering from advanced solid tumors.

Additionally, the abstract AMA30 presents a proof-of-concept for a novel approach that employs artificial transcription factors to establish gene-ON and gene-OFF states, thereby broadening the applications of cytoDRiVE to include the regulation of secreted proteins and mRNA or siRNA expression.

The poster presentation will take place from 6:00 to 7:30 PM Central Time, providing an opportunity for attendees to engage with the innovative research being conducted by Obsidian Therapeutics.

During the presentation, Michael Gallo from Obsidian Therapeutics will highlight novel applications of the cytoDRiVE technology, which enables precise regulation of therapeutic proteins by fusing them to drug-responsive domains.

Obsidian Therapeutics, located in Cambridge, Massachusetts, is at the forefront of developing engineered cell and gene therapies aimed at tackling intractable diseases through its innovative cytoDRiVE technology.

The company is scheduled to present preclinical data from its cytoDRiVE platform at the upcoming American Society of Gene and Cell Therapy Annual Meeting on May 13, 2025.

This advanced regulatory capability is essential for gene and cell therapies, facilitating precise genetic control and addressing the complexities associated with repeat dosing of biologics.